Demographic data from the two trials
| BALTI-P (n=61) | VINDALOO (n=68) | P value | |
| Age (years), median IQR | 64 (65–72) | 67 (60–72) | 0.110 |
| Weight (kg), median IQR | 75 (60–84) | 77 (68–94) | 0.049 |
| Height (cm), median IQR | 171 (167–175) | 173 (168–177) | 0.413 |
| Current smoking | 16 (26.7%) | 9 (13.4%) | 0.075 |
| Histology | Adenocarcinoma 13 (22.8%) Squamous 42 (73.7%) Benign 2 (3.5%) | Adenocarcinoma 58 (85.3%) Squamous 10 (14.7 %) Benign 0 (0.0%) | 0.134 |
| Hypertension, n (%) | 22 (40.7%) | 27 (40.3%) | 1.00 |
| Ischaemic heart disease, n (%) | 4 (7.40%) | 5 (7.46%) | 1.00 |
| Diabetes mellitus | 5 (9.26%) | 8 (11.9%) | 0.771 |
| Chronic lung disease | 5 (9.26%) | 9 (13.4%) | 0.574 |
| Venous thromboembolic disease | 3 (5.56%) | 9 (13.4%) | 0.342 |
| Beta blockers, n (%) | 4 (7.41%) | 16 (23.9%) | 0.025 |
| Aspirin, n (%) | 9 (16.7%) | 11 (16.4%) | 1.00 |
| Dihydropyridine | 8 (13.1%) | 7 (10.3%) | 0.784 |
| Statin | 11 (20.4%) | 22 (32.8%) | 0.153 |
| ACE inhibitor or angiotensin II receptor antagonist | 11 (20.4%) | 13 (19.6%) | 1.00 |
| Preoperative haemoglobin (g/dL), mean (SD) | 121 (15) | 126 (18) | 0.080 |
| Mean tidal volume (mL/kg), mean (SD) | 6.9 (1.9) | 6.1 (1.4) | 0.011 |
| Duration of surgery | 385 (318–454) | 373 (321–419) | 0.494 |
| Duration of OLV (min), median (IQR) | 155 (130–188) | 150 (130–195) | 0.794 |
| Fluid administered (mL/kg), median (IQR) | 31 (24–46) | 41 (30–52) | 0.012 |
| Regional anaesthesia used, n (%) | 51 (92.7%) | 55 (84.6%) | 0.254 |
| Remifentanil | 13 (24.5%) | 5 (8.33%) | 0.022 |
| Dexamethasone | 8 (15.0%) | 20 (66.7%) | 0.030 |
| Ketamine | 0 (0.0%) | 14 (22.2%) | <0.0001 |
| Thoracoscopy | 10 (17.9%) | 22 (35.5%) | 0.039 |
| Laparoscopy | 10 (21.7%) | 8 (12.7%) | 0.455 |
BALTI-P, Beta Agonist Lung Injury Trial-Prevention; OLV, one lung ventilation; VINDALOO, Vitamin D to Prevent Acute Lung Injury Following Oesophagectomy.